Guardian Pharmacy Services (GRDN) saw its shares rise 9.1% during the last trading session, closing at $37.25. This surge was driven by an increase in trading volume, contrasting with a 1.9% gain over the past month. The company’s growth in stock price reflects increasing investor confidence in its service-oriented model within the long-term care pharmacy market and its data-driven healthcare solutions.
The company is expected to report quarterly earnings of $0.24 per share, marking a 14.3% year-over-year increase, with anticipated revenues of $329.68 million—a slight rise of 0.1% from the previous year. Additionally, the consensus EPS estimate has been revised 4.8% higher in the last month, suggesting potential for further stock price appreciation.
In comparison, Akebia Therapeutics (AKBA) ended the last trading session down 1.5% at $1.32, with a consensus EPS estimate for the upcoming report shifted down by 233.3%, reflecting a lack of investor confidence. Akebia currently holds a Zacks Rank of #5 (Strong Sell), while Guardian Pharmacy carries a Zacks Rank of #1 (Strong Buy).
